inh1 Antibody

What is INH1 Antibody and what is its target protein?

INH1 Antibody is a polyclonal antibody raised in rabbits that targets the INH1 protein from Saccharomyces cerevisiae (Baker's yeast). The target protein, INH1 (Uniprot No. P01097), functions as an inhibitory protein that can regulate ATP synthase activity in yeast mitochondria. The antibody is specifically generated against recombinant Saccharomyces cerevisiae (strain ATCC 204508 / S288c) INH1 protein and is designed for research applications only, not for diagnostic or therapeutic procedures .

What are the validated applications for INH1 Antibody?

INH1 Antibody has been validated for several research applications, primarily ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot (WB) for the identification of target antigens. While these are the core validated applications, researchers should perform preliminary experiments to optimize conditions for their specific experimental systems. Similar to other research antibodies, optimization may involve adjusting concentration, incubation time, and blocking conditions to achieve optimal signal-to-noise ratios .

How should INH1 Antibody be stored to maintain its activity?

For optimal preservation of antibody activity, INH1 Antibody should be stored at either -20°C or -80°C upon receipt. Repeated freeze-thaw cycles should be avoided as they can lead to protein denaturation and loss of antibody binding capacity. The antibody is typically supplied in a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative. This formulation helps maintain antibody stability during long-term storage. For working solutions, aliquoting the antibody into smaller volumes before freezing is recommended to minimize freeze-thaw cycles .

What controls should be included when using INH1 Antibody in Western blot experiments?

When designing Western blot experiments with INH1 Antibody, researchers should implement a comprehensive control strategy:

• Positive control: Include lysates from wild-type S. cerevisiae known to express INH1

• Negative control: Use lysates from INH1 knockout strains or non-yeast organisms

• Loading control: Implement standard housekeeping proteins for yeast (e.g., actin, GAPDH)

• Primary antibody control: Perform parallel blots omitting the primary antibody

• Isotype control: Use a non-specific rabbit IgG at the same concentration

This multi-control approach allows researchers to verify antibody specificity and distinguish true signals from background or cross-reactivity. Similar control strategies are utilized in antibody validation studies for other research antibodies where methodological rigor is essential to ensure experimental validity .

What are the optimal dilution parameters for INH1 Antibody in different applications?

While optimal antibody dilution should be determined empirically for each specific experimental setup, the following starting parameters are recommended:

The optimization process should include titration experiments to determine the concentration that provides the highest specific signal with minimal background. This methodological approach is consistent with standard practices in antibody-based detection systems, where the balance between sensitivity and specificity is critical .

How can researchers validate INH1 Antibody specificity for their particular experimental system?

Validation of antibody specificity should follow a multi-pronged approach:

• Genetic validation: Compare signal between wild-type and INH1 knockout/knockdown samples

• Molecular weight verification: Confirm detection at the expected molecular weight (predicted for INH1)

• Peptide competition assay: Pre-incubate antibody with purified INH1 protein/peptide and demonstrate signal reduction

• Orthogonal detection methods: Corroborate results using alternative detection methods such as mass spectrometry

• Cross-species reactivity testing: Test against related species to establish specificity boundaries

This comprehensive validation strategy mirrors approaches used in rigorous antibody characterization studies, ensuring that experimental findings accurately reflect the biological phenomena under investigation .

What are common causes of non-specific binding when using INH1 Antibody and how can they be mitigated?

Non-specific binding can compromise experimental results and may arise from several sources:

For Western blots specifically, using freshly prepared blocking buffer with 5% dried milk powder can significantly reduce background issues. The optimization of antibody concentration is critical, as dilutions typically range from hundreds to thousands of times depending on the specific antibody and detection method .

How should researchers interpret discrepancies between predicted and observed molecular weights when using INH1 Antibody?

Discrepancies between predicted and observed molecular weights occur frequently in protein research and may indicate:

• Post-translational modifications: Phosphorylation, glycosylation, or other modifications can increase apparent molecular weight

• Protein isoforms: Alternative splicing or processing may generate variants with different sizes

• Incomplete denaturation: Remaining secondary structures can affect protein migration

• Technical factors: Gel percentage, running conditions, and marker calibration can influence apparent size

When encountering such discrepancies, researchers should perform additional validation experiments, including mass spectrometry analysis to confirm protein identity, deglycosylation or dephosphorylation treatments to assess modifications, and alternative lysis conditions to ensure complete denaturation. This analytical approach is consistent with rigorous protein characterization methodologies used in antibody research .

How can INH1 Antibody be adapted for immunoprecipitation studies of protein-protein interactions?

For adapting INH1 Antibody to immunoprecipitation (IP) studies investigating protein-protein interactions:

• Pre-clearing: Remove non-specific binding proteins by pre-incubating lysates with protein A/G beads

• Antibody coupling: Covalently couple INH1 Antibody to activated beads to prevent antibody co-elution

• Crosslinking optimization: Determine optimal crosslinker concentration and time for capturing transient interactions

• Stringency balance: Adjust wash buffer composition to maintain specific interactions while reducing background

• Elution strategy: Develop selective elution conditions that preserve interaction partner integrity

While specific IP protocols for INH1 Antibody are not provided in the search results, these approaches align with established methodologies used for other antibodies in IP applications, such as those described for integrase antibodies and other research-grade polyclonal antibodies .

What considerations are important when using INH1 Antibody for detecting conformational changes in the target protein?

Detecting conformational changes in target proteins requires specialized experimental approaches:

• Native vs. denaturing conditions: Compare antibody binding under non-denaturing and denaturing conditions

• Epitope mapping: Identify the specific epitope recognized by the antibody to understand conformational sensitivity

• Limited proteolysis: Combine with proteolytic fingerprinting to reveal structural changes

• Differential scanning fluorimetry: Use in conjunction with the antibody to monitor thermal stability shifts

• Hydrogen-deuterium exchange: Combine with mass spectrometry to map conformational dynamics

These advanced approaches draw from principles established in antibody engineering and epitope mapping studies, where understanding the structural basis of antibody-antigen interactions is critical for interpreting conformational data .

How can researchers integrate INH1 Antibody into multiplexed detection systems?

Integrating INH1 Antibody into multiplexed detection systems requires careful consideration of several factors:

• Antibody labeling: Select appropriate fluorophores or tags with minimal spectral overlap

• Cross-reactivity assessment: Validate absence of cross-reactivity with other antibodies in the multiplex panel

• Signal normalization: Develop calibration standards for quantitative comparisons

• Sequential detection: Design sequential stripping and reprobing protocols if simultaneous detection is problematic

• Imaging parameters: Optimize acquisition settings to prevent signal bleeding between channels

These multiplexing strategies build upon methods used in protein microarray analysis and high-throughput antibody specificity studies, where simultaneous detection of multiple targets demands rigorous control of detection parameters and cross-reactivity .

What quality control metrics should researchers use to evaluate batch-to-batch consistency of INH1 Antibody?

To ensure experimental reproducibility, researchers should evaluate batch-to-batch consistency using these quality control metrics:

These quality control approaches reflect best practices in antibody production and validation, ensuring that experimental results remain comparable across different production lots .

How should researchers analyze potential cross-reactivity of INH1 Antibody with homologous proteins?

Analysis of cross-reactivity with homologous proteins should follow a systematic approach:

• Sequence alignment: Identify proteins with sequence similarity to INH1, particularly in the immunogen region

• Epitope prediction: Use computational tools to predict potential cross-reactive epitopes

• Heterologous expression: Express identified homologs in a controlled system

• Competitive binding assays: Perform assays with purified homologous proteins

• Cross-species testing: Test antibody against lysates from related yeast species with homologous proteins

This methodological framework draws from approaches used in antibody specificity and cross-reactivity studies, where understanding the molecular basis of antibody binding is essential for accurate interpretation of experimental results .